Welcome to our dedicated page for Boston Scien Cp news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scien Cp stock.
Boston Scientific Corporation (NYSE: BSX) is a global medical technology company whose news flow reflects activity across cardiovascular, neuromodulation, urology, endoscopy and other therapeutic areas. Company announcements frequently describe new agreements to acquire medical technology firms, clinical and regulatory milestones for key product platforms, and detailed quarterly financial results.
Recent news includes a definitive agreement to acquire Penumbra, Inc. in a cash and stock transaction. Penumbra has developed mechanical thrombectomy and neurovascular devices to treat conditions such as pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, heart attack and aneurysms, with products like the Lightning Bolt and Lightning Flash computer assisted vacuum thrombectomy systems and peripheral embolization technologies. Boston Scientific has also announced an agreement to acquire Valencia Technologies Corporation, adding the eCoin implantable tibial nerve stimulation system for urge urinary incontinence, and an agreement to acquire Nalu Medical, Inc., developer of the Nalu Neurostimulation System for peripheral nerve stimulation in chronic pain.
In addition to acquisition news, Boston Scientific regularly issues earnings releases detailing net sales by business and region, growth rates on reported, operational and organic bases, and commentary on segment performance in MedSurg and Cardiovascular. These releases often highlight regulatory approvals, such as expanded labeling for the FARAPULSE Pulsed Field Ablation System or CE marks for devices like the WATCHMAN FLX Pro Left Atrial Appendage Closure Device, as well as clinical study results, including long-term data from deep brain stimulation trials.
Investors and observers following BSX news can also expect updates on investor conferences, investor day events, and governance matters disclosed through press releases and Form 8-K filings. This page aggregates such coverage, offering a centralized view of Boston Scientific’s strategic transactions, product developments, financial updates and corporate announcements over time.
Boston Scientific Corporation (NYSE: BSX) announced the completion of a €3.0 billion public offering of senior notes by its subsidiary, American Medical Systems Europe B.V. The offering includes various notes maturing from 2025 to 2034, with interest rates ranging from 0.750% to 1.875%. The net proceeds will fund a tender offer for up to $2.5 billion of senior notes and redeem certain existing notes. The company plans to use any remaining funds for debt repayment and general purposes, aiming to optimize its capital structure.
Boston Scientific Corporation (BSX) has priced a public offering of €3.0 billion in senior notes with various maturity dates from 2025 to 2034. The offering includes €1 billion of 0.750% notes due 2025 and additional notes due in later years with yields ranging from 1.375% to 1.875%. Proceeds will fund a $2.5 billion tender offer for existing senior notes and cover redemptions and associated costs. The offering is expected to close on March 8, 2022, subject to customary conditions.
Boston Scientific Corporation (BSX) has initiated a cash tender offer for up to $2.5 billion of its outstanding senior notes, as of March 2, 2022. The offer encompasses several series of notes with different maturity dates and acceptance prioritization. Tendering is open until March 29, 2022, with early tender benefits available until March 15, 2022. The company may redeem unpurchased notes subsequently. Barclays Capital, BofA Securities, and Citigroup Global Markets are managing the offer.
Boston Scientific announced promising results from the SURPASS analysis, evaluating real-world outcomes of the WATCHMAN FLX™ LAAC Device, at the CRT 2022 meeting. The study included over 16,000 patients with non-valvular atrial fibrillation. Key findings showed a low major adverse event rate of 0.37% at seven days post-implant, and only 0.28% of patients experienced ischemic stroke within 45 days. The device was successfully implanted in 97.6% of cases. Ongoing data collection through 2024 will further evaluate long-term outcomes.
Boston Scientific Corporation (BSX) has finalized its acquisition of Baylis Medical Company for $1.75 billion. This strategic move aims to enhance BSX's position in the growing cardiology market by integrating Baylis's advanced access solutions with BSX's existing electrophysiology and structural heart offerings. The acquisition is expected to be accretive to adjusted earnings per share starting in 2022, with potential for increased accretion subsequently. However, GAAP earnings may initially reflect dilution due to related expenses.
Boston Scientific Corporation (NYSE: BSX) will participate in SVB Leerink's 11th Annual Global Healthcare Conference on February 17, 2022. Executives Dan Brennan and Lauren Tengler will engage in a 30-minute Q&A session at approximately 9:20 a.m. EST. A live webcast will be accessible on the company's Investor Relations webpage. A replay will be available about an hour after the event's conclusion. Boston Scientific is a leader in medical technology, continually advancing healthcare solutions.
Boston Scientific reported Q4 2021 net sales of $3.127 billion, up 15.4% year-over-year, exceeding guidance. The net income was $80 million or $0.06 per share, down from $196 million or $0.14 per share a year ago. Adjusted EPS rose to $0.45 from $0.23. For FY 2021, total net sales reached $11.888 billion, up 19.9%, with a net income of $985 million ($0.69 per share). The company initiated the MODULAR ATP clinical trial and secured a 75% payment increase for Rezūm™ Water Vapor Therapy. Guidance for 2022 estimates sales growth of 6-8%.
Boston Scientific Corporation (NYSE: BSX) will present significant findings at the 25th North American Neuromodulation Society annual meeting in Orlando, Florida, from Jan. 13-15, 2022. Key highlights include a late-breaking presentation on the COMBO study, demonstrating the effectiveness of the WaveWriter™ Spinal Cord Stimulator System over two years. Additionally, updates on collaborations with IBM Research will showcase innovative AI-driven approaches to assess patient pain states.
Over 20 abstracts will be presented, emphasizing Boston Scientific's commitment to personalized chronic pain therapies.
Boston Scientific Corporation (NYSE: BSX) will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 8:15 a.m. EST. CEO Mike Mahoney, CFO Dan Brennan, and VP Lauren Tengler will present and engage in Q&A. Additionally, a conference call to discuss the fourth quarter financial results for 2021 will be held on February 2, 2022, at 8:00 a.m. EST. The financial results will be announced prior to the call. Both events will be accessible via webcast at investors.bostonscientific.com.
Boston Scientific (BSX) has launched the MODULAR ATP clinical trial to assess the safety and efficacy of its mCRM™ Modular Therapy System, integrating the EMBLEM™ MRI Subcutaneous Implantable Defibrillator and the EMPOWER™ Modular Pacing System. This trial will enroll up to 300 patients across 50 centers in the U.S., Canada, and Europe to evaluate the system's complication-free rates, communication success, and pacing thresholds. The S-ICD is shown to prevent sudden cardiac death and has been successfully used in over 100,000 patients, enhancing patient care while minimizing invasive procedures.